Aidi Injection, Compound Kushen Injection, or Kanglaite Injection: Which Is the Best Partner with Systemic Chemotherapy for Patients with HCC? A Network Meta-Analysis
Joint Authors
Zhong, Xiang-Gen
Dou, Dou
Zhang, Ze-yu
Wu, Zhi-yuan
Qiu, Xu-dong
Source
Evidence-Based Complementary and Alternative Medicine
Issue
Vol. 2020, Issue 2020 (31 Dec. 2020), pp.1-11, 11 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2020-08-21
Country of Publication
Egypt
No. of Pages
11
Main Subjects
Abstract EN
Objective.
The aim of this network meta-analysis (NMA) was to explore the effectiveness of different traditional Chinese medicine injections (TCMIs) combined with systemic chemotherapy for the treatment of hepatocellular carcinoma (HCC).
Methods.
A comprehensive search for randomized controlled trials (RCTs) was performed with regard to different TCMIs for treating HCC in seven electronic databases up to November 2019.
The quality assessment of the included RCTs was conducted according to the Cochrane risk of bias tool.
The objective response rate (ORR), clinical benefit rate (CBR), and Karnofsky performance score (KPS) data were extracted.
The network meta-analysis used the network package in Stata software to analyse the data and draw a map of the evidence summarizing the direct and indirect comparisons.
Results.
A total of 1697 articles were retrieved through the comprehensive search.
Twenty RCTs focusing on Aidi injection, compound Kushen injection, and Kanglaite injection as adjuvant therapies to chemotherapy were included, involving a total of 1418 patients.
The NMA statistics showed that all three indicators (ORR, CBR, and KPS) were better in the combined treatment group of TCMIs with chemotherapy than that in the single treatment group of chemotherapy alone.
Kanglaite injection tended to be better than the other two in terms of primary outcome, but there was not a significant difference.
The combined treatment group had fewer adverse reactions than the single treatment group.
Moreover, several articles reported that TCMIs combined with chemotherapy could increase the number of CD3+ and CD4+ T lymphocytes and the ratio of CD4+/CD8+ T lymphocytes.
Conclusions.
TCMIs combined with systemic chemotherapy could be an effective and safe treatment option for patients with HCC.
Kanglaite injection showed a tendency to be better than the other two kinds of injections in terms of ORR.
Nevertheless, additional results from multicentre trials and high-quality studies will be pivotal for supporting our findings.
American Psychological Association (APA)
Dou, Dou& Zhang, Ze-yu& Wu, Zhi-yuan& Qiu, Xu-dong& Zhong, Xiang-Gen. 2020. Aidi Injection, Compound Kushen Injection, or Kanglaite Injection: Which Is the Best Partner with Systemic Chemotherapy for Patients with HCC? A Network Meta-Analysis. Evidence-Based Complementary and Alternative Medicine،Vol. 2020, no. 2020, pp.1-11.
https://search.emarefa.net/detail/BIM-1156594
Modern Language Association (MLA)
Dou, Dou…[et al.]. Aidi Injection, Compound Kushen Injection, or Kanglaite Injection: Which Is the Best Partner with Systemic Chemotherapy for Patients with HCC? A Network Meta-Analysis. Evidence-Based Complementary and Alternative Medicine No. 2020 (2020), pp.1-11.
https://search.emarefa.net/detail/BIM-1156594
American Medical Association (AMA)
Dou, Dou& Zhang, Ze-yu& Wu, Zhi-yuan& Qiu, Xu-dong& Zhong, Xiang-Gen. Aidi Injection, Compound Kushen Injection, or Kanglaite Injection: Which Is the Best Partner with Systemic Chemotherapy for Patients with HCC? A Network Meta-Analysis. Evidence-Based Complementary and Alternative Medicine. 2020. Vol. 2020, no. 2020, pp.1-11.
https://search.emarefa.net/detail/BIM-1156594
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1156594